Pranay Kathuria, MD
Nephrology · Tulsa, OKNPI 1073583431
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (52.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Travere Therapeutics, Inc. accounts for 67.2% of it on its own, with 22 other manufacturers making up the rest. Among nephrology clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 115 payments — averaging $180.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Travere Therapeutics, Inc.$14K
- Calliditas Therapeutics US Inc.$2K
- Amgen$2K
- AstraZeneca$658
- Boehringer Ingelheim$485
- Bayer$220
- plus $1K from 17 others
What the payments were for
- Consulting fees$10,81952%
- Speaking & faculty fees$1,2256%
- Travel & lodging$3,88319%
- Food & beverage$4,64022%
- Education$1911%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Travere Therapeutics, Inc. | 30 | $13,948 |
| Calliditas Therapeutics US Inc. | 9 | $2,341 |
| Amgen(2 entities) | 20 | $1,899 |
| AstraZeneca(2 entities) | 11 | $658 |
| Boehringer Ingelheim | 10 | $485 |
| Bayer | 7 | $220 |
| GSK | 2 | $197 |
| Amarin Pharma, Inc. | 1 | $125 |
| Daiichi Sankyo Inc. | 1 | $122 |
| Lilly USA, LLC | 1 | $109 |
| Fresenius USA Marketing, Inc. | 2 | $105 |
| Mallinckrodt Enterprises LLC | 1 | $100 |
| Novartis | 4 | $89 |
| Otsuka America Pharmaceutical, Inc. | 3 | $75 |
| Merck | 3 | $57 |
| Novo Nordisk | 2 | $45 |
| Baxter Healthcare | 1 | $43 |
| Mallinckrodt Hospital Products Inc. | 2 | $38 |
| Veloxis Pharmaceuticals, Inc. | 1 | $30 |
| Ardelyx, Inc. | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Vifor Pharma, Inc. | 1 | $16 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,758 in reported general payments places this provider in the 95th percentile of 106 nephrology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 27 | $109,284 |
| Thiola EcTiopronin | 12 | $95,419 |
| FarxigaDapagliflozin Propanediol | 68 | $77,404 |
| JardianceEmpagliflozin | 54 | $65,506 |
| Lanthanum Carbonate | 17 | $45,415 |
| EliquisApixaban | 23 | $23,066 |
| Sevelamer Carbonate | 38 | $6,747 |
| Torsemide | 269 | $5,774 |
| Cinacalcet Hcl | 18 | $5,769 |
| Valsartan | 99 | $2,601 |
| Clonidine | 14 | $2,354 |
| Calcium Acetate | 25 | $2,334 |
| Eplerenone | 21 | $2,118 |
| Potassium Chloride | 79 | $2,089 |
| Carvedilol | 206 | $2,018 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $105 | $109,28427 claims |
| AstraZenecaFarxiga | $658 | $77,40468 claims |
| Boehringer IngelheimJardiance | $485 | $65,50654 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 106 nephrology providers in Oklahoma.
Other nephrology in Tulsa
- Sunil AgrawalTulsa$40K
- Kevin FuTulsa$14K
- Diptesh GuptaTulsa$13K
- Janet RussellTulsa$12K
- Bobby MuthalalyTulsa$12K
- Narottam RegmiTulsa$12K
- Alpana PasrichaTulsa$9K
- Reza AzadiTulsa$9K
- Christine WilsonTulsa$8K
- Kusum BhandariTulsa$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.